Patents by Inventor A. Brian Jones

A. Brian Jones has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090233947
    Abstract: Compounds of formula (I) which are useful as therapeutic compounds, particularly in the treatment of pain and other conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1, also known as TRPV1).
    Type: Application
    Filed: May 10, 2006
    Publication date: September 17, 2009
    Inventors: Tracy Bayliss, Rebecca Elizabeth Brown, Gregory John HollingWorth, A. Brian Jones
  • Patent number: 7495020
    Abstract: A class of 2-aryloxy-2-arylalkanoic acids comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions.
    Type: Grant
    Filed: January 18, 2006
    Date of Patent: February 24, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Alan D. Adams, A. Brian Jones, Joel P. Berger, James F. Dropinski, Alexander Elbrecht, Kun Liu, Karen Lamb MacNaul, Guo-Qiang Shi, Derek J. Von Langen, Gaochao Zhou
  • Patent number: 7442701
    Abstract: The present invention provides a compound of formula (I): wherein V represents NR5, O, S, SO or S(O)2; W and X each independently represent CH or N; Y represents N, CH or C—Ar2, with the proviso that at least one, but no more than two, of W, X and Y are N; Z represents CH or C—Ar2, with the proviso that when Y is N or CH then Z is C—Ar2, and with the further proviso that when Y is C—Ar2 then Z is CH; Ar1 represents a fused 9 or 10 membered heterobicyclic ring system containing one, two, three or four heteroatoms selected from nitrogen, oxygen and sulfur, wherein at least one of the rings in said ring system is aromatic; Ar2 represents an aromatic ring selected from phenyl, pyridyl, pyrimidinyl and pyridazinyl which is optionally fused and substituted; R1 represents halogen, hydroxy, oxo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, hydroxyC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkoxy, C3-7cycloalkyl, C3-7cycloalkoxy, C3-5cycloalkylC1-4alkyl, cyano, nitro, SR6, SOR6, SO2R6, COR6, NR3COR6, CON
    Type: Grant
    Filed: November 14, 2003
    Date of Patent: October 28, 2008
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Peter Blurton, Frank Burkamp, Stephen Robert Fletcher, Gregory John Hollingworth, A. Brian Jones, Edward Giles McIver, Christopher Richard Moyes, Lauren Rogers
  • Patent number: 7329659
    Abstract: The present invention provides a compound of formula (I): in which Ar and R1 are phenyl or a heteroaromatic group, R2 is generally hydrogen, R3 is hydrogen or alkyl and X, Y and Z are generally CH or N as VR-1 antagonists; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising it; its use in therapy; use of it to manufacture medicaments to treat pain or inflammation; and methods of treating pain or inflammation
    Type: Grant
    Filed: April 5, 2004
    Date of Patent: February 12, 2008
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Peter Blurton, Frank Burkamp, Stephen Robert Fletcher, A. Brian Jones, Edward Giles McIver
  • Patent number: 7285563
    Abstract: The present invention provides compounds of formula (I); pharmaceutically acceptable salts and N-oxides thereof in which A, B, D and E are C or N with the proviso that one or more are N, R1, R2, R3, R4, R5 and R6 are simple substituents, n is 0-3 and y is an aryl, heteroaryl, carbocyclyl or fused-carbocyclyl group; as VR-1 antagonists for treating conditions or diseases in which pain and/or inflammation predominates; the use of the same for manufacturing medicaments, pharmaceutical compositions comprising them and methods of treatment utilizing them
    Type: Grant
    Filed: March 21, 2003
    Date of Patent: October 23, 2007
    Inventors: Rebecca Elizabeth Brown, Victoria Alexandra Doughty, Gregory John Hollingworth, A. Brian Jones, Matthew John Lindon, Christopher Richard Moyes, Lauren Rogers
  • Patent number: 7125865
    Abstract: The present invention relates to novel LXR ligands of Formula I and the pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.
    Type: Grant
    Filed: July 21, 2003
    Date of Patent: October 24, 2006
    Assignee: Merck & Co., Inc.
    Inventors: A. Brian Jones, Alan D. Adams, Ahren I. Green, Shaei Y. Huang, Bruno Tse, Clare E. Gutteridge, Yuan Cheng
  • Patent number: 7091230
    Abstract: A class of 2-aryloxy-2-arylalkanoic acids comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions.
    Type: Grant
    Filed: February 5, 2002
    Date of Patent: August 15, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Alan D. Adams, A. Brian Jones, Joel P. Berger, James F. Dropinski, Alexander Elbrecht, Kun Liu, Karen Lamb MacNaul, Guo-Qiang Shi, Derek J. Von Langen, Gaochao Zhou
  • Publication number: 20060040947
    Abstract: the present invention provides a compound of formula (I): wherein V represents NR5, O, S, SO or S(O)2; W and X each independently represent CH or N; Y represents N, CH or C—Ar2, with the proviso that at least one, but no more than two, of W, X and Y are N; Z represents CH or C—Ar2, with the proviso that when Y is N or CH then Z is C—Ar2, and with the further proviso that when Y is C—Ar2 then Z is CH; Ar1 represents a fused 9 or 10 membered heterobicyclic ring system containing one, two, three or four heteroatoms selected from nitrogen, oxygen and sulfur, wherein at least one of the rings in said ring system is aromatic; Ar2 represents an aromatic ring selected from phenyl, pyridyl, pyrimidinyl and pyridazinyl which is optionally fused and substituted; R1 represents halogen, hydroxy, oxo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, hydroxyC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkoxy, C3-7cycloalkyl, C3-7cycloalkoxy, C3-5cycloalkylC1-4alkyl, cyano, nitro, SR6, SOR6, SO2R6, COR6, NR3COR6, CON
    Type: Application
    Filed: November 14, 2003
    Publication date: February 23, 2006
    Inventors: Peter Blurton, Frank Burkamp, Sttephen Fletcher, Gregory Hollingworth, A. Brian Jones, edward McIver, Christopher Moyes, Lauren Rogers
  • Patent number: 6908934
    Abstract: Compounds of Formula I and the pharmaceutically acceptable salts and esters thereof, wherein Z is selected from the group consisting of: (a) Formula Ia ?and (b) Formula Ib are novel LXR agonists and are useful in the treatment of dyslipidemic conditions particularly depressed levels of HDL cholesterol.
    Type: Grant
    Filed: May 30, 2002
    Date of Patent: June 21, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Alan D. Adams, Aileen Bouffard, James F. Dropinski, Clare E. Gutteridge, A. Brian Jones, Weiguo Lui, John George Ondeyka, Ali Shiafee, Sheo Bux Singh
  • Patent number: 6852738
    Abstract: A class of acyl sulfamides comprises compounds that are potent ligands for PPAR gamma and generally have antagonist or partial agonist activity. The compounds may be useful in the treatment, control or prevention of obesity, non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, inflammation, and other PPAR gamma mediated diseases, disorders and conditions.
    Type: Grant
    Filed: January 25, 2002
    Date of Patent: February 8, 2005
    Assignee: Merck & Co., Inc.
    Inventors: A. Brian Jones, John J. Acton, III
  • Publication number: 20050014807
    Abstract: Compounds of Formula I and the pharmaceutically acceptable salts and esters thereof, are novel LXR ligands and are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.
    Type: Application
    Filed: November 18, 2002
    Publication date: January 20, 2005
    Inventors: Alan Adams, Shaei Huang, Bruno Tse, A. Brian Jones
  • Publication number: 20040266849
    Abstract: The present invention relates to novel LXR ligands of Formula (I) and the pharmaceutically acceptable salts and esters thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.
    Type: Application
    Filed: June 15, 2004
    Publication date: December 30, 2004
    Inventors: Alan D Adams, Shaei Y Huang, Bruno Tse, Ahren I Green, A Brian Jones
  • Publication number: 20040092596
    Abstract: A class of 2-aryloxy-2-arylalkanoic acids comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions.
    Type: Application
    Filed: July 30, 2003
    Publication date: May 13, 2004
    Inventors: Alan D. Adams, A Brian Jones, Joel P Berger, James F Dropinski, Alexander Elbrecht, Kun Liu, Karen Lamb MacNaul, Guo-Qiang Shi, Derek J Von Langen, Gaochao Zhou
  • Publication number: 20040073037
    Abstract: A class of acyl sulfamides comprises compounds that are potent ligands for PPAR gamma and generally have antagonist or partial agonist activity. The compounds may be useful in the treatment, control or prevention of obesity, non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, inflammation, and other PPAR gamma mediated diseases, disorders and conditions.
    Type: Application
    Filed: July 29, 2003
    Publication date: April 15, 2004
    Inventors: A. Brian Jones, John J. Acton III
  • Publication number: 20030125357
    Abstract: Compounds of Formula I 1
    Type: Application
    Filed: May 30, 2002
    Publication date: July 3, 2003
    Inventors: Alan D. Adams, Aileen Bouffard, James F. Dropinski, Clare E. Gutteridge, A. Brian Jones, Weiguo Lui, John George Ondeyka, Ali Shiafee, Sheo Bux Singh
  • Patent number: 6569879
    Abstract: A class of aryloxyacetic acids comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions.
    Type: Grant
    Filed: August 17, 2001
    Date of Patent: May 27, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Kun Liu, Libo Xu, A. Brian Jones
  • Publication number: 20020173663
    Abstract: A class of aryloxyacetic acids comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions.
    Type: Application
    Filed: August 17, 2001
    Publication date: November 21, 2002
    Inventors: Kun Liu, Libo Xu, A. Brian Jones
  • Patent number: 5840835
    Abstract: Compounds of the formula ##STR1## are inhibitors of peptide binding to major histocompatibility complex type II proteins and may be used in the treatment and prevention of autoimmune diseases including: rheumatoid arthritis, Type I diabetes, multiple sclerosis, lupus erythematosis, Graves disease and pemphigus. The present invention also provides novel compositions, methods of treatment employing compounds of the present invention and methods of manufacture of the compounds of structural formula (I).
    Type: Grant
    Filed: October 28, 1996
    Date of Patent: November 24, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Alan D. Adams, A. Brian Jones
  • Patent number: 5817757
    Abstract: Compounds of the formula ##STR1## are inhibitors of peptide binding to major histocompatibility complex type II proteins and are useful in the treatment and prevention of autoimmune diseases including: rheumatoid arthritis, Type I diabetes, multiple sclerosis, lupus erythematosis, Graves disease and pemphigus. The present invention also provides novel compositions, methods of treatment employing the compounds of the present invention and methods of manufacture of the compounds of structural formula (I).
    Type: Grant
    Filed: October 28, 1996
    Date of Patent: October 6, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Alan D. Adams, A. Brian Jones, Victoria K. Lombardo, Richard L. Tolman
  • Patent number: 5719296
    Abstract: Compounds of the formula ##STR1## are inhibitors of peptide binding to major histocompatibility complex type II proteins and are useful in the treatment and prevention of autoimmune diseases including: rheumatoid arthritis, Type I diabetes, multiple sclerosis, lupus erythematosis, Graves disease and pemphigus. The present invention also provides novel compositions, methods of treatment employing the compounds of the present invention and methods of manufacture of the compounds of structural formula (I).
    Type: Grant
    Filed: October 28, 1996
    Date of Patent: February 17, 1998
    Assignee: Merck & Co., Inc.
    Inventors: John J. Acton, III, Alan D. Adams, Jeffrey D. Hermes, A. Brian Jones, William Hugh Parsons, Peter J. Sinclair